Advertisement

ADVERTISEMENT

Colorectal

Conference Coverage
Panitumumab Plus mFOLFOX6 Significantly Improves OS in Metastatic Colorectal Cancer
06/29/2022

Janelle Bradley

Janelle Bradley
Findings from the phase 3 PARADIGM trial reveal panitumumab combined with mFOLFOX6 significantly improved OS vs bevacizumab plus mFOLFOX6 among patients with RAS wild-type and left-sided metastatic colorectal cancer.
Findings from the phase 3 PARADIGM trial reveal panitumumab combined with mFOLFOX6 significantly improved OS vs bevacizumab plus mFOLFOX6 among patients with RAS wild-type and left-sided metastatic colorectal cancer.
Findings from the phase 3...
06/29/2022
Oncology
Early On-Set CRC: A Biologically Distinct Threat? - Part II
Videos
Early On-Set CRC: A Biologically Distinct Threat? - Part II
03/15/2021
In part 2 of this series, Andrea Cercek, MD, discusses the clinical findings, molecular drivers/alterations, and further research for "Early On-Set Colorectal Cancer: A Biologically Distinct Threat?".
In part 2 of this series, Andrea Cercek, MD, discusses the clinical findings, molecular drivers/alterations, and further research for "Early On-Set Colorectal Cancer: A Biologically Distinct Threat?".
In part 2 of this series, Andrea...
03/15/2021
Oncology
Early On-Set CRC: A Biologically Distinct Threat? - Part I
Videos
Early On-Set CRC: A Biologically Distinct Threat? - Part I
03/15/2021
In part 1 of this video series, Andrea Cercek, MD, discusses the background and possible association of hereditary/environmental factors in early-onset CRC.
In part 1 of this video series, Andrea Cercek, MD, discusses the background and possible association of hereditary/environmental factors in early-onset CRC.
In part 1 of this video series,...
03/15/2021
Oncology
Conference Insider
The Nonoperative Management of Rectal Cancer
10/24/2020
Julio Garcia-Aguilar, MD, PhD, provided insight on how nonoperative management of rectal cancer is evolving at the virtual 2020 Great Debates & Updates in Gastrointestinal Malignancies meeting.
Julio Garcia-Aguilar, MD, PhD, provided insight on how nonoperative management of rectal cancer is evolving at the virtual 2020 Great Debates & Updates in Gastrointestinal Malignancies meeting.
Julio Garcia-Aguilar, MD, PhD,...
10/24/2020
Oncology
Recent Advancements in the Treatment of Oligometastatic Cancer
Videos
Recent Advancements in the Treatment of Oligometastatic Cancer
08/15/2020
Christopher Crane, MD, Memorial Sloan Kettering Cancer Center, New York, NY discusses proof of principle for treating oligometastatic colorectal cancer at the virtual 2020 Great Debates and Updates in GI Malignancies.
Christopher Crane, MD, Memorial Sloan Kettering Cancer Center, New York, NY discusses proof of principle for treating oligometastatic colorectal cancer at the virtual 2020 Great Debates and Updates in GI Malignancies.
Christopher Crane, MD, Memorial...
08/15/2020
Oncology
Conference Insider
No Significant Difference in Long-Term Survival With Mitomycin C vs Oxaliplatin for CRC Peritoneal Metastases
07/04/2020
No significant OS disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for CRC peritoneal metastases, according to long-term survival data.
No significant OS disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for CRC peritoneal metastases, according to long-term survival data.
No significant OS disparity...
07/04/2020
Oncology
Conference Insider
First-Line Encorafenib Plus Binimetinib and Cetuximab Shows Promise in BRAF V600E+ mCRC
07/04/2020
Despite having high-risk features, most patients receiving first-line encorafenib plus binimetinib and cetuximab for BRAFV600E+ mCRC in the ANCHOR CRC trial had tumor regression.
Despite having high-risk features, most patients receiving first-line encorafenib plus binimetinib and cetuximab for BRAFV600E+ mCRC in the ANCHOR CRC trial had tumor regression.
Despite having high-risk...
07/04/2020
Oncology
Conference Insider
Study Recommends Preoperative CRT Followed By Nivolumab, Radical Surgery for MSS and MSI-High Advanced Rectal Cancer
07/04/2020
Study findings suggest a regimen comprising nivolumab and radical surgery after chemoradiotherapy as a candidate therapy for locally advanced, MSS and MSI-H CRC.
Study findings suggest a regimen comprising nivolumab and radical surgery after chemoradiotherapy as a candidate therapy for locally advanced, MSS and MSI-H CRC.
Study findings suggest a regimen...
07/04/2020
Oncology
Conference Insider
Considerations When Using Liquid vs Tissue Biopsy for RAS in mCRC With Single Metastatic Sites
07/03/2020
When a plasma-based assay is being used to detect RAS status in patients with mCRC and lung or peritoneal metastasis alone, the maximum diameter and number of lesions should be carefully considered.
When a plasma-based assay is being used to detect RAS status in patients with mCRC and lung or peritoneal metastasis alone, the maximum diameter and number of lesions should be carefully considered.
When a plasma-based assay is...
07/03/2020
Oncology
Videos
The Evolving Therapy Landscape of MSI-High Colon Cancer
12/05/2019
Tanios Bekaii-Saab, MD, talks about the evolving therapy landscape of MSI-high colon cancer.
Tanios Bekaii-Saab, MD, talks about the evolving therapy landscape of MSI-high colon cancer.
Tanios Bekaii-Saab, MD, talks...
12/05/2019
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 20 ⁠–⁠ September 22
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use